Targeting Bcl-xL in esophageal squamous cancer to sensitize to chemotherapy plus TRAIL-induced apoptosis while normal epithelial cells are protected by blockade of caspase 9.
Kim
K
K
Nakagawa
H
H
Fei
P
P
Rustgi
A K
AK
El-Deiry
W S
WS
D017209:Apoptosis / Q000187:drug effects*; D051017:Apoptosis Regulatory Proteins; D053453:Caspase 9; D020169:Caspases / Q000187:drug effects*; D004358:Drug Therapy; D004847:Epithelial Cells / Q000187:drug effects; D004938:Esophageal Neoplasms / Q000188:drug therapy*; D006801:Humans; D008562:Membrane Glycoproteins / Q000494:pharmacology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D053221:TNF-Related Apoptosis-Inducing Ligand; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*; D051020:bcl-X Protein
D051017:Apoptosis Regulatory Proteins; C494811:BCL2L1 protein, human; D008562:Membrane Glycoproteins; D019253:Proto-Oncogene Proteins c-bcl-2; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human; D014409:Tumor Necrosis Factor-alpha; D051020:bcl-X Protein; C506433:CASP9 protein, human; D053453:Caspase 9; D020169:Caspases